Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14611589 | 0.79 | ALDH1A1 (0.33) | ALDH1A1TSHR | |
| SCHEMBL2479329 | 0.77 | FFAR3 (0.38) | ALDH1A1TSHR | |
| SCHEMBL5787669 | 0.75 | LMNA (0.33) | ALDH1A1TSHR | |
| SCHEMBL2078840 | 0.74 | — | — | |
| SCHEMBL8205181 | 0.73 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL9958086 | 0.71 | CHRM2 (0.33) | — | |
| SCHEMBL29086482 | 0.69 | — | — | |
| SCHEMBL3505624 | 0.68 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL18337481 | 0.68 | FFAR3 (0.35) | TSHR | |
| SCHEMBL20094580 | 0.67 | ALDH1A1 (0.37) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4335512-A2 | CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HiberCell, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-3728217-B1 | CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL INC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-11584763-B2 | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-11535635-B2 | — | — | 2022-12-27 | — | — | US | disclosed |
| US-20210253600-A1 | CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL, INC. | 2021-08-19 | — | — | US | disclosed |
| EP-3728217-A1 | CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | Ravenna Pharmaceuticals, Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| US-10568867-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2020-02-25 | — | — | US | disclosed |
| US-10316049-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| EP-3486246-A1 | THIENO[2,3-C]PYRANS AS CFTR MODULATORS | Galapagos N.V. (BE) | 2019-05-22 | — | — | EP | disclosed |
| EP-3394044-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2018-10-31 | — | — | EP | disclosed |
| US-20040152754-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION (A WASHINGTON CORPORATION) | 2004-08-05 | — | — | US | disclosed |
| US-6716871-B2 | OBESITY; INFLAMMATORY DISEASES, DISEASES INVOLVING ELEVATED LEVELS OF CYTOKINES, CENTRAL NERVOUS SYSTEM DISORDERS; 3-HYDROXYALKYL-4-DIALKOXYPHENYL-SUBSTITUTED PYRROLIDINES | ICOS CORPORATION | 2004-04-06 | — | — | US | disclosed |
| US-20040023945-A1 | CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | ICOS CORPORATION | 2004-02-05 | — | — | US | disclosed |
| US-6423710-B1 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION | 2002-07-23 | — | — | US | disclosed |
| US-6329388-B2 | GONADOTROPIN-RELEASING HORMONE ANTAGONIZING ACTIVITY; USEFUL FOR PREVENTING OR TREATING SEX HORMONE-DEPENDENT DISEASES, E.G., SEX HORMONE-DEPENDENT CANCERS (E.G., PROSTATIC CANCER, UTERINE CANCER, BREAST CANCER, PITUITARY TUMOR) | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-12-11 | — | — | US | disclosed |
| US-6297255-B1 | GONADOTROPIN-RELEASING HORMONE ANTAGONIZING ACTIVITY; PREVENTING OR TREATING SEX HORMONE-DEPENDENT DISEASES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-10-02 | — | — | US | disclosed |
| US-6262267-B1 | HAS GONADOTROPIN-RELEASING HORMONE ANTAGONIZING ACTIVITY; USEFUL FOR PREVENTING OR TREATING SEX HORMONE-DEPENDENT DISEASES, E,G., SEX HORMONE-DEPENDENT CANCERS E.G., PROSTATIC CANCER, UTERINE CANCER, BREAST CANCER, PITUITARY TUMOR | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-07-17 | — | — | US | disclosed |
| US-20010001104-A1 | Thienopyridine compounds, their production and use | FURUYA SHUICHI (JP) | 2001-05-10 | — | — | US | disclosed |
| EP-1090010-A1 | THIENOPYRIDINE COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 2001-04-11 | — | — | EP | disclosed |
| WO-2000000493-A1 | THIENOPYRIDINE COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10568867-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | CFTR, ABCB11, PKD1 | ALDH1A1 340/4885TSHR 3576/4885 |
| US-20040023945-A1 | CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE4B, PDE7A | ALDH1A1 1554/4885TSHR 2900/4885 |
| US-20040152754-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | PDE4A, PDE4B, PDE7A | ALDH1A1 1554/4885TSHR 2900/4885 |
| US-20010001104-A1 | Thienopyridine compounds, their production and use | PRLHR, PGR, GNRHR | ALDH1A1 2243/4885TSHR 107/4885 |
| US-11584763-B2 | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | PIP5K1A, PIP5K1B, PI4KA | ALDH1A1 4367/4885TSHR 2587/4885 |
| US-11535635-B2 | — | PIP5K1A, PI4K2A, PIP5K1B | ALDH1A1 2851/4885TSHR 3865/4885 |
| US-10316049-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | ALDH1A1 4260/4885TSHR 2808/4885 |
| US-20210253600-A1 | CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | PIP5K1A, PIP5K1B, PI4KA | ALDH1A1 4367/4885TSHR 2587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.